Blood pressure medication recalled over possibly containing cancer-causing impurity – Fox News

A Lupin Pharmaceuticals Inc. high blood pressure medication is being remembered by the U.S. Food and Drug Administration (FDA) for possibly containing a “possible human carcinogen.” The voluntary recall includes the companys Irbesartan tablets and Hydrochlorothiazide tablets at the consumer level. CDC INVESTIGATING E. COLI OUTBREAK POSSIBLY TIED TO RAW CAKE BATTERIn an Oct. 14 release, the company said it made the evaluation based upon arise from laboratory screening.” As part of Lupins continuous assessment, analysis exposed that certain evaluated API batches (however not ended up item batches) were above the specification limitation for the pollutant, N-nitrosoirbesartan,” the FDA composed. “Although Lupin has actually gotten no reports of disease that appear to relate to this concern, the company, out of an abundance of care, is remembering all batches of Irbesartan Tablets USP 75mg, 150mg and 300mg and Irbesartan and Hydrochlorothiazide Tablets USP, 150mg/12.5 mg and 300mg/12.5 mg in the United States.”
Lupin Pharmaceuticals, Inc. problems willingly across the country recall of all Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets due to possible presence of N-nitrosoirbesartan pollutant
(FDA)The administration noted that Lupin Pharmaceuticals had actually ceased the marketing of Irbesartan and Irbesartan and HCTZ tabs in January.From October 2018 to Sept. 30, 2021, Lupin Pharmaceuticals reportedly got four reports of health problem from Irbesartan and zero reports from Irbesartan and Hydrochlorothiazide.The Irbesartan tablets USP 75mg, 150mg and 300mg are packaged in 30- and 90-count bottles and were distributed to wholesalers, drug chains, mail-order pharmacies and grocery stores nationwide.RESEARCHERS ASK FDA TO PULL MORE SUNSCREENS OVER POSSIBLE CARCINOGEN”Irbesartan Tablet USP is an angiotensin II receptor blocker suggested for treatment of high blood pressure, to lower blood pressure, diabetic nephropathy in hypertensive clients with type 2 diabetes, a raised serum creatinine and proteinuria,” the FDA described. Irbesartan and Hydrochlorothiazide tablet USP, 150mg/12.5 mg and 300mg/12.5 mg were also packaged in 30- and 90-count bottles and distributed to wholesalers, drug chains, mail-order pharmacies and supermarkets throughout the country.According to the FDA, Lupin Pharmaceuticals is notifying its wholesalers, distributors, drug chains, mail-order drug stores and grocery stores both over the phone and through recall notification, in addition to setting up for the return of all the recalled product lots.The recall notification advised that patients taking Irbesartan tablets USP, 75mg, 150mg and 300mg and Irbesartan and Hydrochlorothiazide tablets USP, 150mg/12.5 mg and 300mg/12.5 mg must continue to do so and contact their pharmacist, physician or medical service provider for details relating to alternative treatment.Any unfavorable responses or quality issues experienced with making use of this product can be reported to the FDAs MedWatch Adverse Event Reporting program either online or by routine mail or fax.CLICK HERE TO GET THE FOX NEWS APPConsumers, wholesalers, distributors or retailers with concerns about the recall need to call Inmar Rx Solutions Inc. at (855) 769-3988/ (855) 769-3989 and remembered lots should be gone back to Inmar Rx Solutions Inc. for reimbursement.The lot number can be found on the side of the bottle label.

Leave a Reply

Your email address will not be published. Required fields are marked *